Skip to main content
SpringerLink
Log in

ICER's revised report confirms evidence is insufficient for aducanumab for Alzheimer's Disease

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. See also see PharmacoEconomics & Outcomes News 880 p36; 803570118.

Reference

  • Institute for Clinical and Economic Review (ICER). In Revised Evidence Report, ICER Confirms Judgment That Evidence is Insufficient to Demonstrate Net Health Benefit of Aducanumab for Patients with Alzheimer?s Disease Internet Document : 2 Jul 2021. Available from: URL: https://icer.org/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER's revised report confirms evidence is insufficient for aducanumab for Alzheimer's Disease. PharmacoEcon Outcomes News 882, 31 (2021). https://doi.org/10.1007/s40274-021-7865-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7865-y

Search

Navigation